Patterns of toxicity following high-dose-rate brachytherapy boost for prostate cancer: Mature prospective phase I/II study results

Radiotherapy and Oncology

Volumn 84, Issue 2, 2007, Pages 128-134

  Duchesne, Gillian Mary ^a   Williams, Scott Garrick ^a   Das, Ram ^a   Tai, Keen Hun ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

High dose rate brachytherapy; Late effects; Prostate cancer; Radiotherapy; Toxicity

Indexed keywords

ANTIANDROGEN;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER GRADING; CONFIDENCE INTERVAL; DOSIMETRY; ENTEROPATHY; ERECTILE DYSFUNCTION; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; INFORMATION PROCESSING; INSTRUMENT; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PENIS ERECTION; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; QUESTIONNAIRE; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RECTUM DISEASE; STATISTICAL ANALYSIS; URINARY TRACT DISEASE; URINARY URGENCY; VALIDATION STUDY;

AGED; AGED, 80 AND OVER; BRACHYTHERAPY; ERECTILE DYSFUNCTION; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RECTAL DISEASES; UROLOGIC DISEASES;

EID: 34548043496     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2007.05.019     Document Type: Article

References (27)

1. TNM classification of malignant tumours 1997. 1997; 5th edition.
2. NCCN practice guidelines in oncology v.2.2005. Prostate cancer. NCCN 2005.
3. Astrom L., Pedersen D., Mercke C., Holmang S., and Johansson K.A. Long-term outcome of high dose rate brachytherapy in radiotherapy of localised prostate cancer. Radiother Oncol 74 (2005) 157-161
4. Bentzen S.M., Dorr W., Anscher M.S., Denham J.W., Hauer-Jensen M., Marks L.B., and Williams J. Normal tissue effects: reporting and analysis. Semin Radiat Oncol 13 (2003) 189-202
5. Boersma L.J., van d., Bruce A.M., Shouman T., Gras L., te V., and Lebesque J.V. Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 Gy) conformal radiotherapy for prostate cancer, using dose-volume histograms. Int J Radiat Oncol Biol Phys 41 (1998) 83-92
6. De Meerleer G.O., Fonteyne V.H., Vakaet L., Villeirs G.M., Denoyette L., Verbaeys A., Lummen N., and De Neve W.J. Intensity-modulated radiation therapy for prostate cancer: late morbidity and results on biochemical control. Radiother Oncol 82 (2007) 160-166
7. Deger S., Boehmer D., Roigas J., Schink T., Wernecke K.D., Wiegel T., Hinkelbein W., Budach V., and Loening S.A. High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer. Eur Urol 47 (2005) 441-448
8. Duchesne G.M., and Peters L.J. What is the alpha/beta ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy [editorial]. Int J Radiat Oncol Biol Phys 44 (1999) 747-748
9. Galalae R.M., Martinez A., Mate T., Mitchell C., Edmundson G., Nuernberg N., Eulau S., Gustafson G., Gribble M., and Kovacs G. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys 58 (2004) 1048-1055
10. Geinitz H., Zimmermann F.B., Thamm R., Erber C., Muller T., Keller M., Busch R., and Molls M. Late rectal symptoms and quality of life after conformal radiation therapy for prostate cancer. Radiother Oncol 79 (2006) 341-347
11. Hanks G.E., Hanlon A.L., Schultheiss T.E., Pinover W.H., Movsas B., Epstein B.E., and Hunt M.A. Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys 41 (1998) 501-510
12. Lee S.P., Leu M.Y., Smathers J.B., McBride W.H., Parker R.G., and Withers H.R. Biologically effective dose distribution based on the linear quadratic model and its clinical relevance. Int J Radiat Oncol Biol Phys 33 (1995) 375-389
13. Lee W.R., Hanks G.E., Hanlon A.L., Schultheiss T.E., and Hunt M.A. Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformal radiation therapy for clinically localized prostate cancer: further evidence for a significant dose effect [see comments]. Int J Radiat Oncol Biol Phys 35 (1996) 251-257
14. Lee W.R., Schultheiss T.E., Hanlon A.L., and Hanks G.E. Urinary incontinence following external-beam radiotherapy for clinically localized prostate cancer. Urology 48 (1996) 95-99
15. Mameghan H., Fisher R., Watt W.H., Meagher M.J., Rosen M., Farnsworth R.H., Tynan A., and Mameghan J. Results of radiotherapy for localised prostatic carcinoma treated at the Prince of Wales Hospital, Sydney. Med J Australia 154 (1991) 317-326
16. Michalski J.M., Winter K., Purdy J.A., Parliament M., Wong H., Perez C.A., Roach M., Bosch W., and Cox J.D. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V. Int J Radiat Oncol Biol Phys 62 (2005) 706-713
17. Michalski J.M., Winter K., Purdy J.A., Perez C.A., Ryu J.K., Parliament M.B., Valicenti R.K., Roach III M., Sandler H.M., Markoe A.M., and Cox J.D. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV. Int J Radiat Oncol Biol Phys 58 (2004) 735-742
18. Michalski J.M., Winter K., Purdy J.A., Wilder R.B., Perez C.A., Roach M., Parliament M.B., Pollack A., Markoe A.M., Harms W., Sandler H.M., and Cox J.D. Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II. Int J Radiat Oncol Biol Phys 56 (2003) 192-198
19. Morton G.C. The emerging role of high-dose-rate brachytherapy for prostate cancer. Clin Oncol (R Coll Radiol) 17 (2005) 219-227
20. Nguyen L.N., Pollack A., and Zagars G.K. Late effects after radiotherapy for prostate cancer in a randomized dose-response study: results of a self-assessment questionnaire. Urology 51 (1998) 991-997
21. Pepe M.S., Longton G., and Thornquist M. A qualifier Q for the survival function to describe the prevalence of a transient condition. Stat Med 10 (1991) 413-421
22. Peters L.J., Withers H.R., and Brown B.W. Complicating issues in complication reporting. Int J Radiat Oncol Biol Phys 31 (1995) 1349-1351
23. Roach III M., Hanks G., Thames Jr. H., Schellhammer P., Shipley W.U., Sokol G.H., and Sandler H. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
24. Schultheiss T.E., Lee W.R., Hunt M.A., Hanlon A.L., Peter R.S., and Hanks G.E. Late GI and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 37 (1997) 3-11
25. Soete G., Arcangeli S., De M.G., Landoni V., Fonteyne V., Arcangeli G., De N.W., and Storme G. Phase II study of a four-week hypofractionated external beam radiotherapy regimen for prostate cancer: report on acute toxicity. Radiother Oncol 80 (2006) 78-81
26. Teshima T., Hanks G.E., Hanlon A.L., Peter R.S., and Schultheiss T.E. Rectal bleeding after conformal 3D treatment of prostate cancer: time to occurrence, response to treatment and duration of morbidity. Int J Radiat Oncol Biol Phys 39 (1997) 77-83
27. Zelefsky M.J., Fuks Z., Hunt M., Yamada Y., Marion C., Ling C.C., Amols H., Venkatraman E.S., and Leibel S.A. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53 (2002) 1111-1116